TrialOphthalmology2024

Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.

Chirag D Jhaveri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.